Pages that link to "Q32122087"
Jump to navigation
Jump to search
The following pages link to Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. (Q32122087):
Displaying 50 items.
- Antifungal resistance in pathogenic fungi (Q28208165) (← links)
- Epidemiology of invasive candidiasis: a persistent public health problem (Q29616758) (← links)
- International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia (Q30453797) (← links)
- Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients (Q31926216) (← links)
- Growth inhibition and ultrastructural alterations induced by Delta24(25)-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organisms (Q33432326) (← links)
- Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies (Q33677651) (← links)
- Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. (Q33683250) (← links)
- Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance (Q33805788) (← links)
- Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice (Q33826450) (← links)
- Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole. (Q33958121) (← links)
- In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. (Q33961573) (← links)
- Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility (Q33962343) (← links)
- Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest (Q33971002) (← links)
- Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada (Q33971521) (← links)
- Antifungal susceptibility testing: practical aspects and current challenges (Q33975757) (← links)
- Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations (Q33975989) (← links)
- Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia (Q33976842) (← links)
- In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum (Q33979873) (← links)
- Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model (Q33981712) (← links)
- Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth (Q33982529) (← links)
- Antifungal pharmacodynamics: review of the literature and clinical applications (Q34083129) (← links)
- Emerging Issues in Nosocomial Fungal Infections (Q34092228) (← links)
- Predictors of outcome in cancer patients with candidemia (Q34155425) (← links)
- Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study (Q34195380) (← links)
- First three reported cases of nosocomial fungemia caused by Candida auris (Q34196357) (← links)
- Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study (Q34202213) (← links)
- Glucan synthase inhibitors as antifungal agents (Q34236665) (← links)
- Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century (Q34294875) (← links)
- Approaches to fungal diagnosis in transplantation (Q34294880) (← links)
- Infectious complications of febrile leukopenia (Q34305085) (← links)
- In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature (Q34317476) (← links)
- In vitro antifungal susceptibility testing (Q34335217) (← links)
- Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo (Q34335230) (← links)
- In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates (Q34452652) (← links)
- Antifungal susceptibility testing. New technology and clinical applications (Q34486480) (← links)
- Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain (Q34489579) (← links)
- Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome (Q34510359) (← links)
- Antifungal drug resistance of pathogenic fungi. (Q34594076) (← links)
- Epidemiology of candidemia in Latin America: a laboratory-based survey (Q34635088) (← links)
- Has antifungal susceptibility testing come of age? (Q34923038) (← links)
- Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers (Q35073043) (← links)
- Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90 (Q35102525) (← links)
- Utility of mould susceptibility testing (Q35587108) (← links)
- Genetically recombinant antibodies: new therapeutics against candidiasis (Q35681522) (← links)
- Recombinant antibodies: a natural partner in combinatorial antifungal therapy (Q35710169) (← links)
- Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. (Q35714132) (← links)
- Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem (Q35738800) (← links)
- Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. (Q35745822) (← links)
- FREQUENCY OF Candida SPECIES IN A TERTIARY CARE HOSPITAL IN TRIANGULO MINEIRO, MINAS GERAIS STATE, BRAZIL. (Q35980145) (← links)
- Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods (Q36022880) (← links)